Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, has announced the launch of KnowU, its groundbreaking wearable non-invasive continuous glucose monitor (CGM). This innovative device marks a significant milestone for the company, following the introduction of its first prototype in June 2023. The KnowU is the result of an accelerated development process over the past eight months.
The KnowU incorporates a sensor that Know Labs plans to submit to the FDA for clearance. This proprietary sensor has undergone rigorous testing in the lab, demonstrating stability and accuracy. It was included in the prototype to validate its performance outside of the lab and has now been miniaturized and made wearable.
The KnowU can be worn with an adhesive, allowing users to easily clip the sensor on and off, or on the wrist or forearm with a strap. The device, which is significantly smaller and lighter than the prototype, features on-board computing power and built-in machine learning capabilities. Designed to optimize the customer experience, the KnowU is expected to last for years, eliminate the need for costly disposables, have a rechargeable battery, and connect seamlessly with a user-friendly companion mobile app.
The introduction of the KnowU brings Know Labs one step closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace. As the company prepares for FDA clinical trials, the KnowU device will support accelerated data collection, including evaluating its performance during continuous wear, on different body locations, and across diverse populations with varying glycemic ranges.
Ron Erickson, CEO and Chairman at Know Labs, emphasized the growing prevalence of diabetes worldwide and the need for accessible and affordable technology to effectively manage the condition. He stated, “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes. The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”
The KnowU is built upon Know Labs’ solid scientific foundation, utilizing its proprietary radiofrequency (RF) sensor. This sensor measures glucose levels using dielectric spectroscopy by rapidly scanning a wide range of RF frequencies. By recording voltage values detected at each frequency and employing trade-secret machine learning algorithms, the KnowU provides real-time continuous blood glucose level monitoring. With over 270 patents issued, pending, and in process, Know Labs holds a leading position as the worldwide IP holder in non-invasive blood glucose monitoring.
Throughout 2024, Know Labs will conduct large-scale external clinical trials to further refine the KnowU device and its algorithms. These trials will contribute to the ongoing development process, ensuring the device meets the highest standards of performance and usability.
Know Labs, Inc. (KNW) is a public company listed on the NYSE American Exchange. The company’s platform technology utilizes spectroscopy to capture unique molecular signatures by directing electromagnetic energy through substances or materials. This patented and patent-pending technology enables the identification and monitoring of analytes in a non-invasive, accessible, and affordable manner. The first application of this technology will be a non-invasive glucose monitor, providing real-time information on blood glucose levels. The product will require U.S. Food and Drug Administration clearance before its market introduction.
Know Labs, Inc. encourages investors to consider the forward-looking statements contained in this release, which highlight the company’s intent, beliefs, and current expectations. While these statements are not guarantees of future performance, they reflect Know Labs’ commitment to innovation and its dedication to improving healthcare outcomes. The company remains focused on addressing the global challenges of diabetes management and delivering cutting-edge solutions to enhance the lives of individuals living with the condition.
For more information about Know Labs and its technology, visit their website at https://www.knowlabs.co/technology.
